Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Hodgkin Lymphoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 58 active trials
6 drugs · 92 active trials
Outside the funnel: Phase not stated 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Meloxicam | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-10 |
| Mocetinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-08 |
| Pexidartinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 3, 2011 |
| Pomalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 2, 2012 |
| Sugemalimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 22, 2018 |
| Tazemetostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 13, 2017 |
| Thalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-07 |
| Thioguanine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1994-03 |
| Tipifarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 24, 2004 |
| Toripalimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 25, 2023 |
| Veliparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-07 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.